Shares of Verona Pharma plc (NASDAQ:VRNA – Get Rating) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock […]
Verona Pharma plc (NASDAQ:VRNA – Get Rating) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,290,000 shares, a growth of 21.8% from the April 15th total of 1,880,000 shares. Based on an average daily trading volume, of 558,400 shares, the short-interest ratio […]
Verona Pharma plc (NASDAQ:VRNA – Get Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,290,000 shares, a growth of 21.8% from the April 15th total of 1,880,000 shares. Based on an average daily volume of 558,400 shares, the short-interest ratio is […]
Verona Pharma plc (NASDAQ:VRNA – Get Rating) General Counsel Claire Poll sold 80,376 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $2.58, for a total value of $207,370.08. Following the transaction, the general counsel now owns 1,979,063 shares of the […]